Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women
暂无分享,去创建一个
D. Narum | S. Rogerson | V. Mwapasa | Andrew Teo | A. Karahalios | F. Kuile | L. Randall | Christelle Buffet | M. Madanitsa | Carole Khairallah | Linda Kalilani Phiri
[1] D. Narum,et al. Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women , 2019, Scientific Reports.
[2] S. Issifou,et al. Persistent Plasmodium falciparum Infection in Women With an Intent to Become Pregnant as a Risk Factor for Pregnancy-associated Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] J. Simpson,et al. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort , 2017, Proceedings of the National Academy of Sciences.
[4] J. Beeson,et al. Functional Antibodies and Protection against Blood-stage Malaria. , 2016, Trends in parasitology.
[5] Steve M. Taylor,et al. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial , 2016, PLoS medicine.
[6] N. Lazar,et al. The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .
[7] A. Wey,et al. Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian Women. , 2016, The American journal of tropical medicine and hygiene.
[8] Steve M. Taylor,et al. The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. , 2015, The Journal of infectious diseases.
[9] P. Siba,et al. Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission , 2015, Malaria Journal.
[10] K. Maleta,et al. The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial , 2015, Malaria Journal.
[11] P. Deloron,et al. Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin , 2015, Emerging infectious diseases.
[12] M. Molyneux,et al. Decreasing malaria prevalence and its potential consequences for immunity in pregnant women. , 2014, The Journal of infectious diseases.
[13] D. Garboczi,et al. Antigen Reversal Identifies Targets of Opsonizing IgGs against Pregnancy-Associated Malaria , 2014, Infection and Immunity.
[14] R. Morrison,et al. Intermittent Preventive Treatment in Pregnant Women Is Associated with Increased Risk of Severe Malaria in Their Offspring , 2013, PloS one.
[15] J. Simpson,et al. New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women , 2012, The Journal of infectious diseases.
[16] Kevin Marsh,et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. , 2012, The Journal of clinical investigation.
[17] Joseph D. Smith,et al. High Avidity Antibodies to Full-Length VAR2CSA Correlate with Absence of Placental Malaria , 2012, PloS one.
[18] Q. Bassat,et al. Transcription of var genes other than var2csa in Plasmodium falciparum parasites infecting Mozambican pregnant women. , 2011, The Journal of infectious diseases.
[19] Joseph D. Smith,et al. Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins , 2011, Malaria Journal.
[20] K. Maleta,et al. Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics and protection during pregnancy in women receiving intermittent preventive treatment. , 2010, The Journal of infectious diseases.
[21] K. Marsh,et al. Intermittent Preventive Sulfadoxine-Pyrimethamine Treatment of Primigravidae Reduces Levels of Plasma Immunoglobulin G, Which Protects against Pregnancy-Associated Plasmodium falciparum Malaria , 2004, Infection and Immunity.
[22] Kevin Marsh,et al. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria , 2004, The Lancet.
[23] Thomas Lavstsen,et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A‐adhering Plasmodium falciparum involved in pregnancy‐associated malaria , 2003, Molecular microbiology.
[24] M. Valiyaveettil,et al. Gravidity-Dependent Production of Antibodies That Inhibit Binding of Plasmodium falciparum-Infected Erythrocytes to Placental Chondroitin Sulfate Proteoglycan during Pregnancy , 2001, Infection and Immunity.
[25] R. Leke,et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. , 2001, The Journal of infectious diseases.
[26] François Nosten,et al. Maternal antibodies block malaria , 1998, Nature.
[27] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[28] S. Rogerson,et al. A Robust Phagocytosis Assay to Evaluate the Opsonic Activity of Antibodies against Plasmodium falciparum-Infected Erythrocytes. , 2015, Methods in molecular biology.
[29] S. Rogerson,et al. Evaluating IgG Antibody to Variant Surface Antigens Expressed on Plasmodium falciparum Infected Erythrocytes Using Flow Cytometry. , 2015, Methods in molecular biology.
[30] S. Meshnick,et al. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. , 2010, The Lancet. Infectious diseases.
[31] C. Menéndez,et al. The burden of malaria in pregnancy in malaria-endemic areas. , 2001, The American journal of tropical medicine and hygiene.